Table 2. Hardy–Weinberg statistics and case–control analysis for male patients with schizophrenia and healthy controls (GRAS)
(A)
GeneSNPTest for HWE deviation
P‐value totalP‐value controlsP‐value cases
FXR1 rs67630690.1320.9330.038
FXR1 rs26010.7570.5930.911
FXR2 rs344166930.1160.3580.653
FXR2 rs620598330.0890.0150.924
(B)
GeneSNPMAFGenotypeN (%)P‐value
Cases (N = 709)Controls (N = 730)
FMR1 rs256990.416T412 (58.3)455 (62.7)0.091
C294 (41.7)271 (37.3)
FXR1 rs67630690.325AA331 (47.4)319 (44.5)0.872
AT282 (40.3)317 (44.3)
TT86 (12.3)80 (11.2)
FXR1 rs26010.212AA435 (61.7)438 (60.2)0.428
AG237 (33.6)257 (35.3)
GG33 (4.7)33 (4.5)
FXR2 rs344166930.302GG342 (49.3)368 (50.8)0.280
GA287 (41.3)304 (42.0)
AA65 (9.4)52 (7.2)
FXR2 rs620598330.278CC368 (53.0)388 (53.6)0.307
CT274 (39.5)301 (41.6)
TT52 (7.5)35 (4.8)
FMR2 rs2410840.272A514 (73.6)544 (75.6)0.393
G185 (26.5)176 (24.4)
FMR2 rs173183230.069A660 (93.2)687 (94.1)0.505
G48 (6.8)43 (5.9)
FMR2 rs66414820.112A629 (88.7)648 (88.9)0.887
G80 (11.3)81 (11.1)
  • (A) Test for deviation from Hardy–Weinberg equilibrium (HWE) in male schizophrenic individuals (GRAS) and male healthy controls for non‐X‐chromosomal SNP genotypes; significance level after correction for multiple testing < 0.013. (B) No significant differences in genotype frequencies in case–control comparison of male schizophrenic patients (GRAS) with healthy controls.